← Research library

[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression].

Randomized study in people · 2016

What was studied
40 patients during regression of a multiple-sclerosis relapse after steroid treatment
Main finding
No between-group EDSS difference was reported; selected functional and neurophysiological measures differed.

Completed treatment · 17/20 (85%) versus 18/20 (90%)

Reported findings and study design

40 patients recovering from an MS relapse: 20 Cerebrolysin versus 20 saline after methylprednisolone 1,000 mg/day for five days. Cerebrolysin 20 mL/day for ten administrations; follow-up 3–4 weeks.

Population or model 40 patients during regression of a multiple-sclerosis relapse after steroid treatment

Dose, route and schedule

After methylprednisolone 1,000 mg/day for five days, the study used Cerebrolysin 20 mL in 200 mL saline once daily for ten administrations, compared with saline. This was sequential adjunctive treatment during recovery from an MS relapse.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Completed treatment17/20 (85%) versus 18/20 (90%)
Baseline age27.35 (5.65) versus 26.65 (4.93) years
Baseline disease duration29.9 (11.01) versus 30.25 (11.98) months
Baseline EDSS3.5 [2.0;4.5] versus 3.0 [1.5;4.5]
Follow-up EDSS2.0 [1.75;2.5] versus 2.5 [1.75;2.5]No significant between-group difference · p=0.665
MSFC and SDMTGreater improvement in the treated groupp=0.038 and p=0.026
Visual test comparisonNo significant differencep=0.658
Neurophysiological abnormality regression70.59% versus 27.78%p=0.028
Neurophysiological deterioration10% versus 30%p=0.228
Gadolinium-positive MRI lesions14 before versus 12 afterwardFour treated patients only

Small short-term comparison. MRI lesion counts from four treated patients cannot establish remyelination or disease modification.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Short follow-up, attrition and a very small MRI subset limit interpretation. Surrogate changes do not establish remyelination.

Source details

Journal publication

Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.

Sources checked

Citation

Randomized trialEnglish abstract

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR. [Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Study source ↗ · DOI 10.17116/jnevro201611612148-53 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards